Compare Danaos Corporation (DAC) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaos Corporation vs IDEXX Laboratories, Inc. — how do they compare? Danaos Corporation trades at $169.5 (market cap $3.10B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 13× Danaos Corporation's market cap, and Danaos Corporation pays a 2.35% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaos Corporation for 25 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| DAC | IDXX | |
|---|---|---|
Market Cap | $3.10B | $40.43B |
Volume | 286,008 | 692,164 |
Sector | Industrials | Health |
52-Week High | $170.22 | $766.68 |
52-Week Low | $84.05 | $504.70 |
Typical Hold Time | 25 Days | 46 Days |
Enterprise Value | $3.08B | $41.32B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaos Corporation (DAC) trades at $164.48, down 0.88% on the day, with strong fundamental metrics including a low P/E of 5.57 and robust profitability margins. The stock shows a bullish technical trend, trading above key moving averages, with recent earnings consistently beating expectations. The company maintains strong cash flow generation and has declared multiple dividends, reflecting financial health and shareholder returns.
The outlook remains positive given DAC's undervaluation, earnings momentum, and dividend payments. Key risks include shipping industry cyclicality and global trade volatility. Analyst consensus is evenly split between Buy and Hold, indicating cautious optimism amid strong fundamentals and technical strength.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
